40% over­all re­sponse rate (ORR) with a total admin­istered dose of 60 mCi or greater

Forham Park, NJ (Press Release) – Cellectar Bio­sciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the dis­cov­ery, de­vel­op­ment and com­mer­cial­i­za­tion of drugs for the treat­ment of can­cer, to­day an­nounced that a clin­i­cally meaningful 40% over­all re­sponse rate (ORR) was ob­served in the subset of re­frac­tory mul­ti­ple myeloma patients deemed triple class re­frac­tory who re­ceived a total admin­istered dose of 60 mCi or greater. Triple class re­frac­tory is defined as patients re­frac­tory to immuno­modu­la­tory, pro­te­a­some in­hib­i­tors and anti-CD38 anti­body drug classes.

The 40% ORR (6/15 patients) rep­re­sents triple class re­frac­tory …

Covers composition of mat­ter and method of use into 2036 for pro­pri­e­tary PLE analogs in com­bi­na­tion with var­i­ous small mol­e­cule chemo­ther­a­peu­tics

Florham Park, NJ (Press Release) – Cellectar Bio­sciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, de­vel­op­ment and com­mer­cial­i­za­tion of drugs for the treat­ment of cancer, to­day an­nounced that the Euro­pean Patent Office has an­nounced the intent to grant pat­ent num­ber EP3229810 (B1) titled “Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles.” The pat­ent provides composition of mat­ter and use pro­tec­tion for the com­pany’s pro­pri­e­tary PLE, targeted de­livery vehicle analogs in com­bi­na­tion with a broad range of chemo­ther­a­peu­tics such as paclitaxel, gemcitabine, and other classes of small mol­e­cule chemo­ther­a­peu­tic …

Patent covers the phos­pho­lipid ether (PLE) de­livery vehicle com­bined with I-131 and I-125

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, de­vel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced that the Euro­pean Patent Office has granted pat­ent num­ber EP 2440253 titled “Ether and Alkyl Phospholipid Compounds for Treating Cancer and Imaging and Detection of Cancer Stem Cells." The pat­ent provides composition of mat­ter and use pro­tec­tion for the treat­ment and/or diag­nosis of cancer and cancer stem cells for the com­pany’s Phase 2 lead asset CLR 131 and the pro­pri­e­tary PLE analogs …

• 42.8% ORR in mul­ti­ple myeloma at the 75mCi total body dose
• 42.0% ORR and 11% CRR in all non-Hodgkin’s lym­phoma (NHL) patients
• 100% ORR seen in Lymphoplasmacytic Lymphoma / Waldenstrom’s Macro­globu­linemia (LPL / WM) patients
• 76.7% of the mul­ti­ple myeloma patients across all doses tested ex­peri­enced tumor re­duc­tion with a strong dose re­sponse­

Florham Park, NJ (Press Release) – Cellectar Bio­sciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the dis­cov­ery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of can­cer, to­day an­nounced pos­i­tive data from its Phase 2 CLOVER-1 study in patients with re­lapsed / re­frac­tory B-cell lym­phomas. Addi­tionally, the com­pany an­nounced the suc­cess­ful com­ple­tion of its Phase 1 dose escalation study. Data from the stud­ies dem­onstrated ac­­tiv­ity in all in­di­ca­tions tested: mul­ti­ple myeloma (MM), diffuse large B-cell lym­phoma (DLBCL), …

• 30% over­all re­sponse­ rate seen with an average pro­gres­sion free sur­vival of 4.5 months and an ac­ceptable and ex­pec­ted safety profile
• Additional data in patients re­ceiv­ing higher frac­tion­ated doses of CLR 131 antic­i­pated in Jan­u­ary­

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced summary data from 20 patients re­ceiv­ing a single dose of CLR 131 in its Phase 2 CLOVER-1 trial in select re­lapsed / re­frac­tory (RR) B-cell malig­nan­cies. The com­pany had pre­vi­ously an­nounced data from 10 mul­ti­ple myeloma patients re­ceiv­ing a single dose of CLR 131 in Feb­ru­ary 2019, which showed a 30% …

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced that the Euro­pean Com­mis­sion has awarded CLR 131 orphan desig­na­tion for the treat­ment of mul­ti­ple myeloma.

Orphan desig­na­tion is given to medicinal prod­ucts that rep­re­sent a sig­nif­i­cant benefit over existing treat­ments; are in­tended for the treat­ment, prevention or diag­nosis of a dis­ease that is life-threatening or chronically debilitating; and where prev­a­lence of the con­di­tion in the EU is less than 5 in …

• Results dem­onstrated 50% partial re­sponse rate, 50% minimal re­sponse rate, and 100% dis­ease con­trol rate
• Independent Data Monitoring Com­mit­tee de­ter­mines dose to be safe and well tol­er­ated and rec­om­mends study con­tinue to Cohort 7

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced initial results from Cohort 6 in the Com­pany’s on­go­ing Phase 1 clin­i­cal study with CLR 131 in Re­lapsed or Re­frac­tory Multiple Myeloma (R/R MM). The 37.5 mCi/m² frac­tion­ated dose was de­ter­mined to be safe and tol­er­able by the in­de­pen­dent Data Monitoring Com­mit­tee (DMC). Following the deter­mi­na­tion, the Com­pany has ini­ti­ated …